Gilead Sciences

Company

The pharmaceutical company that acquired Kite Pharma for $11.9 billion in 2017, making anti-CD19 CAR T-cell therapy widely available.

Mentioned in 2 videos

Videos Mentioning Gilead Sciences

177 - The development of cancer immunotherapy and its promise for treating advanced cancers

177 - The development of cancer immunotherapy and its promise for treating advanced cancers

Peter Attia MD

The pharmaceutical company that acquired Kite Pharma for $11.9 billion in 2017, making anti-CD19 CAR T-cell therapy widely available.

E104: FTX collapse with Coinbase CEO Brian Armstrong + election results, macro update & more

E104: FTX collapse with Coinbase CEO Brian Armstrong + election results, macro update & more

All-In Podcast

A biopharmaceutical company, its stock performance is highlighted as an example of a defensive sector outperforming tech during the economic downturn.